Bis-Urea Organoselenium Cancer-Cell Screening
Official patent title
Bis urea-based organoselenium compound and method for treating cancer
Arabic title: مركب سيلينيوم عضوي قائم على ثنائي اليوريا وطريقة لعلاج السرطان
Invention
Invention
Problem
Cancer-drug discovery needs compounds that inhibit malignant cells while limiting effects on normal cells. Early cell-line activity must be separated from evidence of safety or therapeutic efficacy in animals and patients.
Why it matters
A synthesizable organoselenium scaffold can provide a lead for structure–activity, selectivity, mechanism, and toxicology studies, but the disclosed evidence remains preclinical and in vitro.
Approach
The patent describes bis-(organoselanyl urea)aryl agents of Formula (I), their synthesis from a selenium aniline and bis-phenyl isocyanate, and in-vitro contact with selected cancer-cell lines.
Who may benefit
Potential beneficiaries include medicinal-chemistry laboratories, oncology researchers, pharmaceutical discovery teams, selenium-chemistry groups, and preclinical toxicology programs.
Potential value
The disclosure provides a defined bis-urea organoselenium scaffold, a synthesis route, and claimed in-vitro growth-inhibition thresholds across eight listed cancer-cell lines.
Background
Background
Organoselenium compounds are investigated in medicinal chemistry because selenium-containing groups can influence redox behavior and cellular pathways. A compound that changes cancer-cell growth may warrant follow-up, but a small inhibition percentage in culture does not establish tumor selectivity, mechanism, exposure, tolerability, or clinical benefit. Normal-cell controls, dose–response relationships, pharmacology, and animal studies are required. Although the source summary discusses administration to a subject, the issued claims supplied here are directed to in-vitro contact with cancer-cell lines.
Technology overview
Technology overview
Formula (I) contains a bis-(organoselanyl urea)aryl structure with specified R1 groups. The synthesis reacts selenium aniline with bis-phenyl isocyanate in an organic solvent, including a stated 2.2:1 reactant ratio and eight-hour stirring embodiment. Claims cover in-vitro contact with HN9, HuH7, FaDu, MCF7, HEPG2, A549, HCT116, and A375 cells. They state at least 5% growth inhibition generally, at least 5% for HCT116, and at least 9% for HN9; these are cell-culture claims, not clinical outcomes.
Potential applications
Potential applications
- In-vitro oncology compound screening.
- Organoselenium structure–activity research.
- Preclinical mechanism and selectivity studies.
- Medicinal-chemistry lead development.
Evidence-supported advantages
Evidence-supported advantages
- Defines a bis-urea organoselenium scaffold.
- Provides a reproducible synthesis concept.
- Lists eight cancer-cell lines for screening.
- Includes disclosed cancer- and non-cancer-cell thresholds.
- Supports follow-on structure–activity studies.
Development stage
Development stage
Chemical synthesis and in-vitro cancer-cell growth-inhibition claims are described; animal pharmacology, animal efficacy and safety, clinical testing, and commercialization were not established. The development stage was not independently verified.
Commercial opportunity
Commercial opportunity
The compound is an early discovery lead. Advancement requires independent dose–response replication, potency and selectivity metrics, mechanism and target identification, metabolism, selenium exposure and off-target toxicology, formulation, pharmacokinetics, animal efficacy and tolerability, scalable synthesis, and regulatory review before any human therapeutic use.
Patent classifications
Patent classifications
WIPO IPC
- C07C391/02Acyclic or carbocyclic compounds
- A61K31/17Preparations for medical, dental or toiletry purposes
CPC
- A61K31/17Preparations for medical, dental or toiletry purposes
- A61P35/00Specific therapeutic activity of chemical compounds or medicinal preparations
- C07C391/02Acyclic or carbocyclic compounds
Inventors
Inventors
- First inventorTarek Ahmed Yousef
- InventorSaad Shaaban
- InventorAhmed A. Al-Karmalawy
- InventorMarwa Sharaky
- InventorHussein Ba-Ghazal
- InventorMohamed Alaasar
Keywords
Keywords
- organoselenium
- bis urea
- cancer cell line
- in vitro
- growth inhibition
- medicinal chemistry
- selenium aniline
Patent document and drawings
Patent document and drawings
The patent publication is mapped to this record. Patent drawings remain within that publication; no separately cleared public media package has been supplied.